AstraZeneca Starts to Slash

Mar. 3.10 | About: AstraZeneca Group (AZN)

OK, I think AstraZeneca (NYSE:AZN) has made an official announcement on this. They're getting out of schizophrenia, bipolar disease, depression, anxiety, acid reflux, thrombosis, ovarian and bladder cancers, systemic scleroderma and hepatitis C. (So much for some of the company's current and recent big-selling areas..)

As for facilities, they're shutting down early R&D in Wilmington and in Lund (Sweden), and the Charnwood site in the UK is closing. I haven't heard if there are other cuts going on in the sites (or therapeutic areas) that are remaining, though.